Thinly traded nano cap Pluristem Therapeutics (NASDAQ:
PSTI) spikes
55% premarket on increased volume in reaction to
preliminary data on the use of its PLX cells in severely ill COVID-19 patients in Israel.
Seven ICU-housed patients with acute respiratory
distress syndrome were treated under a compassionate use program. Six
completed the seven-day follow-up period (the seventh is still within
the period).
All survived. Three are in advanced stages of
weaning from ventilators and four have experienced improvements in
respiratory parameters. One remains on a ventilator but is stable and
one deteriorated. Two patients (some are the same as above) with
multi-organ failure prior to treatment showed clinical recovery in
addition to respiratory improvement.
The company plans to pursue a multinational clinical trial for these patients.
PLX cell therapy utilizes placental cells to
secrete therapeutic proteins that trigger the body’s own repair
mechanisms which allows it to grow blood vessels and deliver oxygenated
blood to damaged tissue, thereby accelerating the healing process.
https://seekingalpha.com/news/3558915-pluristem-jumps-55-premarket-on-positive-effect-of-plx-cells-in-covidminus-19
